Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,010 JPY | +5.12% | +8.07% | +29.39% |
Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
Apr. 25 | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.38 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.39% | 58.76B | A- | ||
+25.83% | 653B | C+ | ||
+27.00% | 556B | B | ||
-6.76% | 354B | C+ | ||
+20.34% | 331B | B- | ||
+3.00% | 296B | C+ | ||
+13.09% | 233B | B+ | ||
+5.46% | 201B | B- | ||
-9.61% | 193B | A+ | ||
-6.26% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4568 Stock
- Ratings Daiichi Sankyo Co., Ltd.